Prime Medicine’s prime editing technology enables precise DNA rewriting without creating double-strand breaks, significantly lowering the risk of unintended genetic modifications. This platform builds on more than 40 FDA-approved cell and gene therapies and addresses a market where cell therapy revenues topped $8.2 billion this year and regenerative medicine could reach $578 billion by 2033.

Transitioning from the edited cell to an approved therapy requires extensive research, multi-phase clinical trials and scaled GMP-compliant manufacturing. Prime Medicine will need to establish robust cell banking, process validation and supply chains, with commercialization milestones likely several years away.